Abstract A212: First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study.

Title
Abstract A212: First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study.
Authors
Keywords
-
Journal
MOLECULAR CANCER THERAPEUTICS
Volume 10, Issue Supplement 1, Pages A212-A212
Publisher
American Association for Cancer Research (AACR)
Online
2012-06-27
DOI
10.1158/1535-7163.targ-11-a212

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now